XML 59 R48.htm IDEA: XBRL DOCUMENT
v3.21.2

Segment Reporting (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2021
Segment Reporting [Abstract] |
Reconciliation of revenue from segments to consolidated | The following tables present our segment information for the three and six months ended June 30, 2021 and 2020 (in thousands). Prior-year segment information (including segments total Adjusted EBITDA) has been restated to conform to the reporting structure change described in Note 1.
| Evolent Health Services |  | Clinical Solutions |  | Intersegment Eliminations |  | Subtotal |  | Corporate (1) |  | Consolidated
Revenue |  |  |  |  |  |  |  |  |  |  |
For the Three Months Ended June 30, 2021 |  |  |  |  |  |  |  |
Transformation services | $ | 2,564 |  |  | $ | — |  |  | $ | — |  |  | $ | 2,564 |  |  | $ | — |  |  | $ | 2,564 |
Platform and operations services | 72,759 |  |  | 147,194 |  |  | (460) |  |  | 219,493 |  |  | — |  |  | 219,493 |
Total revenue | $ | 75,323 |  |  | $ | 147,194 |  |  | $ | (460) |  |  | $ | 222,057 |  |  | $ | — |  |  | $ | 222,057 |
For the Three Months Ended June 30, 2020 |  |  |  |  |  |  |  |
Transformation services | $ | 755 |  |  | $ | — |  |  | $ | — |  |  | $ | 755 |  |  | $ | — |  |  | $ | 755 |
Platform and operations services | 86,432 |  |  | 130,780 |  |  | (668) |  |  | 216,544 |  |  | — |  |  | 216,544 |
Total revenue | $ | 87,187 |  |  | $ | 130,780 |  |  | $ | (668) |  |  | $ | 217,299 |  |  | $ | — |  |  | $ | 217,299 |
| Evolent Health Services |  | Clinical Solutions |  | Subtotal |  | Corporate (1) |  | Segments Total |  |
For the Three Months Ended June 30, 2021 |  |  |  |  |  |  |  |
Adjusted EBITDA | $ | 6,531 |  |  | $ | 13,597 |  |  | $ | 20,128 |  |  | $ | (6,782) |  |  | $ | 13,346 |  |  |
For the Three Months Ended June 30, 2020 |  |  |  |  |  |  |  |
Adjusted EBITDA | $ | 6,948 |  |  | $ | 12,200 |  |  | $ | 19,148 |  |  | $ | (8,629) |  |  | $ | 10,519 |  |  |
| Evolent Health Services |  | Clinical Solutions |  | Intersegment Eliminations |  | Subtotal |  | Corporate (1) |  | Consolidated
Revenue |  |  |  |  |  |  |  |  |  |  |
For the Six Months Ended June 30, 2021 |  |  |  |  |  |  |  |
Transformation services | $ | 2,909 |  |  | $ | — |  |  | $ | — |  |  | $ | 2,909 |  |  | $ | — |  |  | $ | 2,909 |
Platform and operations services | 157,700 |  |  | 277,417 |  |  | (898) |  |  | 434,219 |  |  | — |  |  | 434,219 |
Total revenue | $ | 160,609 |  |  | $ | 277,417 |  |  | $ | (898) |  |  | $ | 437,128 |  |  | $ | — |  |  | $ | 437,128 |
For the Six Months Ended June 30, 2020 |  |  |  |  |  |  |  |
Transformation services | $ | 5,993 |  |  | $ | — |  |  | $ | — |  |  | $ | 5,993 |  |  | $ | — |  |  | $ | 5,993 |
Platform and operations services | 178,222 |  |  | 255,652 |  |  | (1,336) |  |  | 432,538 |  |  | — |  |  | 432,538 |
Total revenue | $ | 184,215 |  |  | $ | 255,652 |  |  | $ | (1,336) |  |  | $ | 438,531 |  |  | $ | — |  |  | $ | 438,531 |
| Evolent Health Services |  | Clinical Solutions |  | Subtotal |  | Corporate (1) |  | Segments Total |  |
For the Six Months Ended June 30, 2021 |  |  |  |  |  |  |  |
Adjusted EBITDA | $ | 12,473 |  |  | $ | 29,573 |  |  | $ | 42,046 |  |  | $ | (13,793) |  |  | $ | 28,253 |  |  |
For the Six Months Ended June 30, 2020 |  |  |  |  |  |  |  |
Adjusted EBITDA | $ | 11,716 |  |  | $ | 19,243 |  |  | $ | 30,959 |  |  | $ | (16,564) |  |  | $ | 14,395 |  |  |
———————— (1)Corporate includes various finance, human resources, legal, executive, and other corporate infrastructure expenses.
Reconciliation of Adjusted EBITDA to net loss | The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net loss attributable to common shareholders of Evolent Health, Inc. for the three and six months ended June 30, 2021 and 2020 (in thousands):
| For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
| 2021 |  | 2020 |  | 2021 |  | 2020
Net loss attributable to common shareholders of Evolent Health, Inc. | $ | (9,107) |  |  | $ | (203,521) |  |  | $ | (18,914) |  |  | $ | (282,273) |
Less: |  |  |  |  |  |  |
Interest income | 68 |  |  | 705 |  |  | 191 |  |  | 1,475 |
Interest expense | (6,274) |  |  | (6,290) |  |  | (12,611) |  |  | (12,571) |
(Provision) benefit for income taxes | (91) |  |  | 3,904 |  |  | (702) |  |  | 3,634 |
Depreciation and amortization expenses | (14,916) |  |  | (15,618) |  |  | (30,103) |  |  | (31,596) |
Equity method investment impairment | — |  |  | — |  |  | — |  |  | (47,133) |
Gain on transfer of membership | — |  |  | — |  |  | 22,969 |  |  | — |
Loss on repayment of debt, net | — |  |  | — |  |  | (19,158) |  |  | — |
Goodwill impairment | — |  |  | (215,100) |  |  | — |  |  | (215,100) |
Gain from equity method investees | 4,879 |  |  | 25,143 |  |  | 12,662 |  |  | 24,731 |
Loss on disposal of assets | — |  |  | — |  |  | — |  |  | (6,447) |
Change in fair value of contingent consideration and indemnification asset | — |  |  | (756) |  |  | 594 |  |  | 3,062 |
Other expense, net | (18) |  |  | 354 |  |  | (32) |  |  | 284 |
Repositioning costs | (663) |  |  | — |  |  | (6,043) |  |  | — |
Stock-based compensation expense | (3,653) |  |  | (3,703) |  |  | (7,359) |  |  | (7,211) |
Severance costs | — |  |  | (30) |  |  | (52) |  |  | (6,133) |
Amortization of contract cost assets | (196) |  |  | (767) |  |  | (323) |  |  | (1,207) |
Strategy and shareholder advisory expenses | (1,513) |  |  | — |  |  | (6,513) |  |  | — |
Acquisition costs | (76) |  |  | (374) |  |  | (2,070) |  |  | (683) |
Gain (loss) from discontinued operations (1) | — |  |  | (1,508) |  |  | 1,383 |  |  | (1,773) |
Adjusted EBITDA | $ | 13,346 |  |  | $ | 10,519 |  |  | $ | 28,253 |  |  | $ | 14,395 |
———————— (1)Includes $1.9 million gain on disposal of discontinued operations for the six months ended June 30, 2021.

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration